Fernando Henao
6 Papers
2 Citations
Fernando Henao is an academic researcher. The author has contributed to research in topics: Internal medicine & Breast cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Erica L. Mayer,Amylou C. Dueck,Miguel Martín,G. Rubovszky,Harold J. Burstein,Meritxell Bellet-Ezquerra,Kathy D. Miller,Nicholas Zdenkowski,Eric P. Winer,Georg Pfeiler,Matthew Bidwell Goetz,Manuel Ruiz-Borrego,Daniel G. Anderson,Zbigniew Nowecki,Sibylle Loibl,Stacy L. Moulder,Alistair Ring,Florian Fitzal,Tiffany A. Traina,Arlene Chan,Hope S. Rugo,Julie Lemieux,Fernando Henao,Alan P. Lyss,Silvia Antolin Novoa,Antonio C. Wolff,Marcus Vetter,Daniel Egle,Patrick G. Morris,Eleftherios P. Mamounas,Miguel Gil-Gil,Aleix Prat,Hannes Fohler,Otto Metzger Filho,Magdalena Schwarz,Carter Dufrane,Debora Fumagalli,Kathy Puyana Theall,D. Lu,Cynthia Huang Bartlett,Maria Koehler,Christian Fesl,Angela DeMichele,Michael Gnant +43 more
TL;DR: The PALLAS trial as discussed by the authors investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine treatment alone in patients with hormone-receptor-positive, HER2-negative, early stage breast cancer.
223
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
L. De La Cruz Merino,María Gion,Jhony A. De la Cruz,JL. Alonso-Romero,Vanesa Quiroga,F. Moreno,R. Andres,Marta Santisteban,Manuel Ramos,Esther Holgado,J. Cortes,Elena López-Miranda,A Cortés,Fernando Henao,Natalia Palazón-Carrión,Luz Milva Rodriguez Rodriguez,I. Ceballos,A Soto,A. Puertes,M Casas,S. Benito,Massimo Chiesa,Susana Bezares,Rosalía Caballero,Carlos Jiménez-Cortegana,Vijctor Sanchez-Margalet,Federico Rojo +26 more
TL;DR: In this paper , a new chemo-immunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine was evaluated in HER2-advanced breast cancer patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.
8
Abstract P4-01-28: PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
Noelia Martínez-Jañez,M. Bellet Ezquerra,Fernando Henao,Luis Manso,Antonio Antón,Pilar Zamora,Serafin Morales Murillo,P. Tolosa,Raquel Andrés,Lourdes Calvo,Elena Galve,Rafael López,Francisco Ayala de la Peña,Sara López-Tarruella,Laia Boronat,Tamara Martos,Jose Ignacio Chacon,Isabel Alvarez,Juan De La Haba-Rodriguez,Fernando Moreno Antón +19 more
TL;DR: Martínez-Jáñez et al. as mentioned in this paper evaluated the efficacy and safety of palbociclib treatment under real-life conditions in patients with HR+/HER2-MBC.
2
Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
Eva Ciruelos,Cristina Saura,Xavier Gonzalez-Farre,Javier Salvador Bofill,Maria Vidal,I. Blancas,Elena López-Miranda,M. Iglesias,Miriam Arumí,Mireia Margeli,Catarina Pulido,Serafin Morales,Fernando Henao,Pilar Sánchez,Sara Alves,Diogo Martins Branco,Joan Gasent,Pedro Sánchez-Rovira,Ana Godoy,José Luís Passos-Coelho,Santiago Escrivá-de-Romaní,Juan Manuel Ferrero-Cafiero,Tomás Pascual,Aleix Prat +23 more
TL;DR: SOLTI-1718 NEREA aims to evaluate whether EGFR/ERBB2 axis inhibition by neratinib improves efficacy in terms of progression-free survival (PFS) in patients with advanced HR+/HER2-negative disease resistant to endocrine treatment (ET).
1
Abstract P3-01-01: Unicentric experience with icdk4/6 in metastatic breast cancer
Fernando Henao,Esteban Nogales Fernández,Lourdes Sevilla-Ortega,Ruben De Toro Salas,Natalia Palazón Carrión,Maria del Carmen Álamo de la Gala,Alberto Sanchez-Camacho Mejías,María Luisa Sánchez León,L. De La Cruz Merino +8 more
TL;DR: Henao et al. as mentioned in this paper presented a real-life study with experience in a single center with the three icdk4/6 currently marketed with a cohort of more than 150 patients.